News | August 08, 2025
Biocon Q1 FY26 PAT slips 95% to Rs. 31.4 Cr
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
Key takeaways of recent quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
